Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    ATH434

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alterity Therapeutics Releases Q1 FY26 Cash Flow Report
    Alterity Therapeutics Releases Q1 FY26 Cash Flow Report

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178235/0/en/Alterity-Therapeutics-Appendix-4C-Q1-FY26-Quarterly-Cash-Flow-Report.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    Alterity Reveals Positive ATH434 Ph 2 Trial Results At Congress
    Alterity Reveals Positive ATH434 Ph 2 Trial Results At Congress

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164032/0/en/Alterity-Therapeutics-Presents-Positive-Data-from-ATH434-Phase-2-Trial-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    Alterity Therapeutics To Present At 2025 Parkinson's Disease
    Alterity Therapeutics To Present At 2025 Parkinson's Disease

    02 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160282/0/en/Alterity-Therapeutics-to-Deliver-Multiple-Presentations-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html

    GLOBENEWSWIRE
    02 Oct 2025
    Share Share
    Alterity Therapeutics Presents New Data from ATH434 Phase 2 Trial
    Alterity Therapeutics Presents New Data from ATH434 Phase 2 Trial

    10 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/10/3059151/0/en/Alterity-Therapeutics-Presents-Encouraging-New-Data-from-its-ATH434-Phase-2-Trial-in-Multiple-System-Atrophy-at-the-American-Academy-of-Neurology-Annual-Meeting.html

    GLOBENEWSWIRE
    10 Apr 2025
    Share Share
    Alterity Therapeutics to Present Positive ATH434 Phase 2 Results
    Alterity Therapeutics to Present Positive ATH434 Phase 2 Results

    03 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/03/3055030/0/en/Alterity-Therapeutics-to-Deliver-an-Oral-Presentation-of-the-Positive-ATH434-Phase-2-Trial-Results-at-the-American-Academy-of-Neurology-Annual-Meeting.html

    GLOBENEWSWIRE
    03 Apr 2025
    Share Share
    Alterity Reports Positive Interim Data For ATH434 In MSA Trial
    Alterity Reports Positive Interim Data For ATH434 In MSA Trial

    17 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/17/2914458/0/en/Alterity-Therapeutics-Reports-Positive-Interim-Data-from-ATH434-202-Phase-2-Clinical-Trial-in-Multiple-System-Atrophy.html

    GLOBENEWSWIRE
    17 Jul 2024
    Share Share